Stock Events

Stock Events

Alseres Pharmaceuticals 

$0.01
2
+$0+0% Friday 20:00

Statistics

Day High
0.01
Day Low
0.01
52W High
0.01
52W Low
0.01
Volume
66
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13AugExpected
Q3 2012
Q4 2012
Q1 2013
Q2 2013
Q3 2013
Q1 2014
Q2 2014
-93.38
-78.46
-63.54
-48.61
Expected EPS
N/A
Actual EPS
-52.39

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurological diseases, directly competing in the CNS therapeutic area similar to Alseres.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly develops drugs for neurological conditions, overlapping with Alseres' focus on CNS disorders.
Novartis
NVS
Mkt Cap237.61B
Novartis offers medications for multiple sclerosis and Alzheimer's, competing in the neurology space.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a strong portfolio in CNS treatments, including drugs for Alzheimer's disease, directly competing with Alseres.
Merck
MRK
Mkt Cap214.76B
Merck develops therapies for Alzheimer’s disease, which is a key area of focus for Alseres.
Rogers
ROG
Mkt Cap1.57B
Roche is involved in neurology and CNS disorders, with significant investments in Alzheimer's and multiple sclerosis.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical specializes in generic drugs including CNS treatments, competing in the same therapeutic market.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a growing interest in neurodegenerative diseases, particularly with their R&D in Parkinson’s and Alzheimer’s.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has initiatives in neuroscience, particularly in neurodegenerative diseases, aligning them as a competitor.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a dedicated neuroscience R&D unit focusing on diseases like Parkinson’s, making them a direct competitor.

About

Biotechnology
Health Technology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.
Show more...
CEO
Peter Savas
Employees
3
Country
US
ISIN
US0211522026

Listings

0 Comments

Share your thoughts

FAQ

What is Alseres Pharmaceuticals stock price today?▼
The current price of ALSE is $0.01 USD — it has increased by +0% in the past 24 hours. Watch Alseres Pharmaceuticals stock price performance more closely on the chart.
What is Alseres Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alseres Pharmaceuticals stocks are traded under the ticker ALSE.
What were Alseres Pharmaceuticals earnings last quarter?▼
ALSE earnings for the last quarter are -52.39 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does Alseres Pharmaceuticals have?▼
As of April 01, 2026, the company has 3 employees.
In which sector is Alseres Pharmaceuticals located?▼
Alseres Pharmaceuticals operates in the Professional, Scientific, and Technical Services sector.
When did Alseres Pharmaceuticals complete a stock split?▼
Alseres Pharmaceuticals has not had any recent stock splits.
Where is Alseres Pharmaceuticals headquartered?▼
Alseres Pharmaceuticals is headquartered in Auburndale, US.